| Document |
Document Title |
|
WO/2023/245040A1 |
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer and reverse fleximer nucleoside analogues having increased flexibility and ability to alter their conformat...
|
|
WO/2023/241699A1 |
The present disclosure relates to a cyclopentyl adenosine derivative and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, whe...
|
|
WO/2023/245037A1 |
The disclosure provides processes for preparing the compound of formula (VIa-1) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIa-1) are also provided.
|
|
WO/2023/241587A1 |
The present invention provides an oligonucleotide having a cyclic phosphonate modification. The oligonucleotide of the present invention exhibits one or more among enhanced stability, reduced off-target toxicity, and enhanced effectiveness.
|
|
WO/2023/239190A1 |
The present invention relates to a method for preparing 4'-thio-5-aza-2'-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient p...
|
|
WO/2023/235362A1 |
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end ...
|
|
WO/2023/233410A1 |
The present invention relates to crystalline polymorph Form I of benzyl N2- ((benzyloxy)carbonyl)-N4-(l-((2R,3S,4S,5R)-3,4-dihydroxy-5-(
hydroxymethyl)tetrahydrofuran- 2-yl)-2-oxo-l,2-dihydropyrimidin-4-yl)-L-asparaginate (Compound 1), p...
|
|
WO/2023/229884A2 |
3'-blocked nucleotides, methods of deblocking the same, and methods of synthesizing polynucleotides using the same are provided herein. In some examples, a nucleotide is disposed within the aperture on the first side of a nanopore. The n...
|
|
WO/2023/228177A1 |
The present invention relates to novel compositions comprising (l-((2R,3S,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-l,2-d
ihydropyrimidin-4-yl)-L-asparagine (also known as BST-236, Astarabine® or Aspacytarabine)...
|
|
WO/2023/230061A2 |
Disclosed herein are compounds of formula or pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.
|
|
WO/2023/224108A1 |
Provided is a nucleoside represented by formula (1). [In formula (1): R1 represents a hydroxyl group, a hydroxyl group in which the hydrogen atom is substituted by an alkyl or alkenyl group, or a protected hydroxyl group; R2 represents a...
|
|
WO/2023/225042A1 |
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to pro...
|
|
WO/2023/219427A1 |
The present invention relates to a pyrrolopyrimidinone carboxamide compound represented by chemical formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for treating cancer, co...
|
|
WO/2023/217094A1 |
Disclosed in the present invention are a preparation method and the use of 2'-deoxyguanosine, guanosine and a composition of 2'-deoxyguanosine and guanosine. The present invention belongs to the technical field of the prevention and cont...
|
|
WO/2023/219114A1 |
The mRNA cap analog contains a functional group selected from the following: amino group, carboxylic acid active ester groups, aminooxy group, hydrazino group, carbonyl group, thiol group, haloacetyl groups, Michael acceptor functional g...
|
|
WO/2022/221241A9 |
Compounds comprising 5-position modified pyrimidines are provided. Further, polynucleotides, such as aptamers, comprising at least one 5-position modified pyrimidine are provided. Methods of selecting and using such polynucleotides, such...
|
|
WO/2023/215506A1 |
In one aspect, the disclosed technology relates to nanopore sequencing with a polynucleotide comprising a plurality of nucleotides, wherein each nucleotide comprises a linker construct between two positions of the nucleotide, wherein the...
|
|
WO/2023/215516A2 |
Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2'-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present di...
|
|
WO/2023/212656A1 |
Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell po...
|
|
WO/2023/209586A1 |
The present invention relates to new glycomimetic molecules which selectively bind to the L-SIGN receptor, finding application in the medical field and, in particular, in the prevention and treatment of viral infections, in the immunothe...
|
|
WO/2023/205206A1 |
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods fo...
|
|
WO/2023/202604A1 |
The present invention falls within the technical field of medicinal chemistry, and specifically relates to an antiviral nucleoside analogue, and a pharmaceutical composition and the use thereof. The nucleoside analogue of the present inv...
|
|
WO/2023/205786A1 |
The invention provides substituted 2',3'-didehydro-3'-deoxy-4'-ethynylthymidines and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase activity, their use for inhibiting HERV-K reverse t...
|
|
WO/2023/178133A9 |
The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcrip...
|
|
WO/2023/201072A1 |
In various embodiments of the present disclosure, antiviral 6-azauridine compounds are described having a structure represented by Formula (I) and comprising 6-azauridine tri-ester, phosphoramidate, and cyclic phosphoramidate monophospha...
|
|
WO/2023/200760A1 |
The invention relates to new tunicamycin structures comprising N-acyl groups metabolically integrated into the terminus of the TUN via the Streptomyces branched chain fatty acid pathways and variants thereof, and methods of preparing suc...
|
|
WO/2023/197791A1 |
The present invention relates to a cyclic carbonate nucleoside compound as represented by formula (I), and a pharmaceutically acceptable salt, a crystalline hydrate, a solvate or a tautomer thereof, and further disclosed are a pharmaceut...
|
|
WO/2023/195544A1 |
The present invention provides an enzyme that phosphorylates the 2'-hydroxyl group of an RNA, etc.
|
|
WO/2023/195566A1 |
The present application relates to a RNA vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a polynucleotide prepared therefor, and provides a polynucleotide for inducing an adaptive immune response t...
|
|
WO/2023/192900A1 |
Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with an optionally substituted 3'vinyl blocking group. Also provided herein are methods to prepare such nucleotide and nucleoside molecules. Additionally...
|
|
WO/2023/185812A1 |
Disclosed in the present invention is a method for preparing acetylated cytosine triphosphate and an intermediate thereof. A method for preparing a compound as represented by formula 3, the method comprising the following steps: carrying...
|
|
WO/2023/185282A1 |
Disclosed in the present invention is a long-chain fatty acid prodrug of N4-hydroxycytidine isobutyl ester, the prodrug being freely selected from at least one of a lauroyl prodrug, a myristoyl prodrug, and a palmitoyl prodrug represente...
|
|
WO/2023/179799A1 |
Provided are a porphyrin zinc europium phosphorus cluster material, a preparation method therefor and an application thereof. Lamellar black phosphorus reacts with europium chloride to form europium-doped black phosphorus; and then tetra...
|
|
WO/2023/182530A1 |
Obtained is an excellent anti-CD39 antibody. Provided is an antibody or an antigen-binding fragment that binds to CD39, and contains heavy-chain CDRs 1-3 and light-chain CDRs 1-3 containing a specific amino acid sequence. This antibody m...
|
|
WO/2023/180237A1 |
Provided herein is a method for modifying a polynucleotide or an analogue or derivative thereof, comprising reacting the polynucleotide or analogue or derivative thereof with a compound of formula (I), wherein RH, L1, Ⓛ, R, n and RP ar...
|
|
WO/2023/174278A1 |
The present invention relates to a pharmaceutical composition of an anti-TIM-3 antibody and a hypomethylating agent. Preferably, the demethylating agent is azacitidine or decitabine. The present invention further provides a kit containin...
|
|
WO/2022/183081A9 |
Compounds useful for forming nucleic acids having the structure of Formula (I). Each of R1 or R2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R3 is selected from H, F, O-C1-6 alkyl, O-MOE and a...
|
|
WO/2023/177743A2 |
This disclosure relates to a process for producing Crystalline Beta Nicotinamide Riboside Triacetate Chloride with improved physical property characteristics. A substantially crystalline Beta Nicotinamide Riboside Triacetate Chloride, or...
|
|
WO/2023/172082A1 |
The present invention relates to an insecticide composition comprising a novel emamectin glycoside and, more particularly, to: an insecticide composition comprising a novel emamectin glycoside with a remarkably increased Bursaphelenchus ...
|
|
WO/2023/170279A1 |
The disclosure includes compounds in accordance with Formula (I) or Formula (II) wherein R1, R2, and R3 are defined herein and to methods of making those compounds. That disclosure extends 5 to those compounds for the treatment of neopla...
|
|
WO/2023/165541A1 |
A method for preparing molnupiravir, which comprises: using compound (IV) as a starting material, reacting compound (IV) with isobutyryl chloride or isobutyric anhydride under an alkaline condition to give intermediate compound (V), and ...
|
|
WO/2023/167094A1 |
Disclosed are a 5'-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is a compound represented by formula (I) or a salt thereof. The nucleoside of the present invention has suitable duplex-formi...
|
|
WO/2023/167382A1 |
The present invention relates to N 4-isobutyryloxycytidine analog synthesis and to the anti-viral use thereof against dengue virus, influenza virus, and SARS-CoV-2 virus.
|
|
WO/2023/167908A1 |
Bis-protected, activated guanine monomers or pharmaceutically acceptable salts thereof for use in the synthesis of polymorpholino oligonucleotides and methods of making the bis-protected, activated guanine monomers are provided.
|
|
WO/2023/166160A1 |
The present invention disclose novel process for synthesis of 1,4- dihydronicotinamide riboside (NRH). More particularly, the invention discloses a cost-effective synthesis of 1, 4-dihydronicotinamide riboside (NRH) from Nicotinamide-bet...
|
|
WO/2023/160405A1 |
Provided is a compound NMNH disodium salt, and the present invention in particular relates to a polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutica...
|
|
WO/2023/159930A1 |
The present invention relates to the technical field of genetic engineering, and relates to a compound for RNA capping and an application of the compound. The compound has a structure as shown in formula I. The compound is used to cap mR...
|
|
WO/2023/159042A1 |
Disclosed herein are functionalized oxazine dye compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in nucleic acid amplification reactions. Also disclosed herein are labeled oligonucleotides and l...
|
|
WO/2023/156601A1 |
The present invention relates to radio- and fluorescence-labeled compounds, as well as their use as Diagnostics for Detecting Ecto-5'-Nucleotidase (CD73). The invention is further directed to a pharmaceutical composition comprising said ...
|
|
WO/2023/155909A1 |
Disclosed are a ribavirin analog and use thereof as an embedding group in RNAi, and particularly disclosed is a compound as shown in formula (Z).
|
